{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.ai-analytics.org/api/v1/entity/IBRX/timeline","_source":{"data_provider":"AI Analytics","data_provider_url":"https://api.ai-analytics.org","license":"https://api.ai-analytics.org/license","usage_info":"https://api.ai-analytics.org/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-22T18:18:58.188Z","methodology_url":"https://api.ai-analytics.org/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":8970,"canonical_name":"ImmunityBio, Inc.","cik":"0001326110","uei":null,"lei":null,"duns":null,"ticker":"IBRX"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","open.payments","dol.form5500","hud.housing","irs.bmf"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":34,"clinical":16,"court":2,"open":1},"count":53,"timeline":[{"ts":"2026-07-06","kind":"sec.filing","form_type":"4","title":"4 — ImmunityBio, Inc. — 2026-07-06","url_slug":"/sec/cik-0001326110/4/0001529371-26-000008","accession_number":"0001529371-26-000008","importance":30},{"ts":"2026-07-06","kind":"sec.filing","form_type":"4","title":"4 — ImmunityBio, Inc. — 2026-07-06","url_slug":"/sec/cik-0001326110/4/0001849739-26-000014","accession_number":"0001849739-26-000014","importance":30},{"ts":"2026-07-02","kind":"sec.form144","reporter":"CHERYL L COHEN","title":"Officer","shares":131210,"usd_value":1207132,"security_title":"Common","approx_sale_date":"2026-07-02","accession_number":"0001950047-26-006831","importance":40.2414264},{"ts":"2026-07-02","kind":"sec.insider.s","reporter":"Cohen Cheryl","title":null,"shares":131210,"price_per_share":9.5034,"usd_value":1246941,"security_title":"Common Stock","importance":36.246941114},{"ts":"2026-07-02","kind":"sec.filing","form_type":"144","title":"144 — ImmunityBio, Inc. — 2026-07-02","url_slug":"/sec/cik-0001326110/144/0001950047-26-006831","accession_number":"0001950047-26-006831","importance":30},{"ts":"2026-07-02","kind":"sec.insider.m","reporter":"Cohen Cheryl","title":null,"shares":55979,"price_per_share":2.98,"usd_value":166817,"security_title":"Common Stock","importance":15.16681742},{"ts":"2026-07-01","kind":"sec.form144","reporter":"CHRISTOBEL SELECKY","title":"Director","shares":159478,"usd_value":1396230,"security_title":"Common","approx_sale_date":"2026-07-01","accession_number":"0001950047-26-006714","importance":40.279245978},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Selecky Christobel","title":null,"shares":159478,"price_per_share":9.0236,"usd_value":1439066,"security_title":"Common Stock","importance":36.4390656808},{"ts":"2026-07-01","kind":"sec.filing","form_type":"144","title":"144 — ImmunityBio, Inc. — 2026-07-01","url_slug":"/sec/cik-0001326110/144/0001950047-26-006714","accession_number":"0001950047-26-006714","importance":30},{"ts":"2026-07-01","kind":"sec.filing","form_type":"4","title":"4 — ImmunityBio, Inc. — 2026-07-01","url_slug":"/sec/cik-0001326110/4/0001849739-26-000011","accession_number":"0001849739-26-000011","importance":30},{"ts":"2026-07-01","kind":"sec.insider.m","reporter":"Selecky Christobel","title":null,"shares":124414,"price_per_share":2.99,"usd_value":371998,"security_title":"Common Stock","importance":15.37199786},{"ts":"2026-07-01","kind":"sec.insider.m","reporter":"Selecky Christobel","title":null,"shares":35064,"price_per_share":2.98,"usd_value":104491,"security_title":"Common Stock","importance":15.10449072},{"ts":"2026-06-30","kind":"sec.form144","reporter":"CHRISTOBEL SELECKY","title":"Director","shares":1000,"usd_value":8770,"security_title":"Common","approx_sale_date":"2026-06-30","accession_number":"0001950047-26-006655","importance":40.001754},{"ts":"2026-06-30","kind":"sec.insider.s","reporter":"Selecky Christobel","title":null,"shares":1000,"price_per_share":9,"usd_value":9000,"security_title":"Common Stock","importance":35.009},{"ts":"2026-06-30","kind":"sec.filing","form_type":"144","title":"144 — ImmunityBio, Inc. — 2026-06-30","url_slug":"/sec/cik-0001326110/144/0001950047-26-006655","accession_number":"0001950047-26-006655","importance":30},{"ts":"2026-06-30","kind":"sec.insider.m","reporter":"Selecky Christobel","title":null,"shares":700,"price_per_share":2.98,"usd_value":2086,"security_title":"Common Stock","importance":15.002086},{"ts":"2026-06-30","kind":"sec.insider.m","reporter":"Selecky Christobel","title":null,"shares":300,"price_per_share":2.99,"usd_value":897,"security_title":"Common Stock","importance":15.000897},{"ts":"2026-06-29","kind":"sec.form144","reporter":"CHRISTOBEL SELECKY","title":"Director","shares":95722,"usd_value":833739,"security_title":"Common","approx_sale_date":"2026-06-29","accession_number":"0001950047-26-006608","importance":40.166747724},{"ts":"2026-06-29","kind":"sec.insider.s","reporter":"Selecky Christobel","title":null,"shares":95722,"price_per_share":9.0075,"usd_value":862216,"security_title":"Common Stock","importance":35.862215915},{"ts":"2026-06-29","kind":"sec.insider.m","reporter":"Selecky Christobel","title":null,"shares":33549,"price_per_share":2.99,"usd_value":100312,"security_title":"Common Stock","importance":15.10031151},{"ts":"2026-06-29","kind":"sec.insider.m","reporter":"Selecky Christobel","title":null,"shares":32173,"price_per_share":2.98,"usd_value":95876,"security_title":"Common Stock","importance":15.09587554},{"ts":"2026-06-29","kind":"sec.insider.m","reporter":"Selecky Christobel","title":null,"shares":30000,"price_per_share":2.84,"usd_value":85200,"security_title":"Common Stock","importance":15.0852},{"ts":"2026-06-10","kind":"sec.filing","form_type":"8-K","title":"8-K — ImmunityBio, Inc. — 2026-06-10","url_slug":"/sec/cik-0001326110/8-k/0001326110-26-000064","accession_number":"0001326110-26-000064","importance":35},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — ImmunityBio, Inc. — 2026-06-10","url_slug":"/sec/cik-0001326110/4/0001349193-26-000003","accession_number":"0001349193-26-000003","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — ImmunityBio, Inc. — 2026-06-10","url_slug":"/sec/cik-0001326110/4/0001364846-26-000003","accession_number":"0001364846-26-000003","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — ImmunityBio, Inc. — 2026-06-10","url_slug":"/sec/cik-0001326110/4/0001371407-26-000003","accession_number":"0001371407-26-000003","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — ImmunityBio, Inc. — 2026-06-10","url_slug":"/sec/cik-0001326110/4/0001529371-26-000003","accession_number":"0001529371-26-000003","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — ImmunityBio, Inc. — 2026-06-10","url_slug":"/sec/cik-0001326110/4/0001822674-26-000003","accession_number":"0001822674-26-000003","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — ImmunityBio, Inc. — 2026-06-10","url_slug":"/sec/cik-0001326110/4/0001849739-26-000007","accession_number":"0001849739-26-000007","importance":30},{"ts":"2026-06-05","kind":"sec.filing","form_type":"4","title":"4 — ImmunityBio, Inc. — 2026-06-05","url_slug":"/sec/cik-0001326110/4/0001647994-26-000008","accession_number":"0001647994-26-000008","importance":30},{"ts":"2026-06-04","kind":"sec.form144","reporter":"Simon Barry J.","title":"Officer, Director","shares":268033,"usd_value":2946500,"security_title":"COMMON","approx_sale_date":"2026-06-04","accession_number":"0001949846-26-000345","importance":40.589300034},{"ts":"2026-06-04","kind":"sec.insider.s","reporter":"Simon Barry J.","title":"","shares":23033,"price_per_share":7.1769,"usd_value":165306,"security_title":"Common Stock","importance":35.1653055377},{"ts":"2026-06-04","kind":"sec.filing","form_type":"144","title":"144 — ImmunityBio, Inc. — 2026-06-04","url_slug":"/sec/cik-0001326110/144/0001949846-26-000345","accession_number":"0001949846-26-000345","importance":30},{"ts":"2026-05-18","kind":"sec.filing","form_type":"8-K","title":"8-K — ImmunityBio, Inc. — 2026-05-18","url_slug":"/sec/cik-0001326110/8-k/0001193125-26-229153","accession_number":"0001193125-26-229153","importance":35},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"ImmunityBio, Inc.","title":"ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer","security_title":null,"status":"AVAILABLE","accession_number":"NCT06810141","excerpt":"[\"NMIBC\"]","importance":25},{"ts":"2026-05-11","kind":"clinical.trial","reporter":"ImmunityBio, Inc.","title":"A Study to Assess Anktiva in Patients With Long Covid-19.","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07108036","excerpt":"[\"Long COVID\"]","importance":45},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"ImmunityBio, Inc.","title":"Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia","security_title":"PHASE3","status":"WITHDRAWN","accession_number":"NCT07492875","excerpt":"New protocol developed","importance":80},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"ImmunityBio, Inc.","title":"Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.","security_title":"PHASE2","status":"WITHDRAWN","accession_number":"NCT06765954","excerpt":"Study was redeveloped into a new protocol","importance":80},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"ImmunityBio, Inc.","title":"Immunotherapy Before and After Surgery","security_title":"PHASE2","status":"WITHDRAWN","accession_number":"NCT06765902","excerpt":"Study was redeveloped into a new protocol","importance":80},{"ts":"2026-05-04","kind":"clinical.trial","reporter":"ImmunityBio, Inc.","title":"Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07524257","excerpt":"[\"NSCLC (Advanced Non-small Cell Lung Cancer)\",\"Metastatic NSCLC\"]","importance":60},{"ts":"2026-05-04","kind":"clinical.trial","reporter":"ImmunityBio, Inc.","title":"Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07125872","excerpt":"[\"Relapsed B-Cell Non Hodgkin Lymphoma\"]","importance":45},{"ts":"2026-05-04","kind":"clinical.trial","reporter":"ImmunityBio, Inc.","title":"Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT06334991","excerpt":"[\"Non-Hodgkin Lymphoma Refractory/ Relapsed\"]","importance":30},{"ts":"2026-04-29","kind":"clinical.trial","reporter":"ImmunityBio, Inc.","title":"Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer","security_title":"PHASE1","status":"NOT_YET_RECRUITING","accession_number":"NCT07488884","excerpt":"[\"Pancreatic Cancer Resectable\",\"Pancreatic Cancer\"]","importance":30},{"ts":"2026-04-29","kind":"clinical.trial","reporter":"ImmunityBio, Inc.","title":"Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)","security_title":null,"status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05981131","excerpt":"[\"Non Muscle Invasive Bladder Cancer\"]","importance":25},{"ts":"2026-04-17","kind":"court.docket","reporter":"cacd","title":"Roland Davies v. Patrick Soon-Shiong","security_title":"850 Securities/Commodities","excerpt":"28:1331 Fed. Question: Securities Violation","accession_number":"2:26-cv-04130","product_type":null,"importance":45},{"ts":"2026-04-15","kind":"clinical.trial","reporter":"ImmunityBio, Inc.","title":"Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer","security_title":"PHASE3","status":"TERMINATED","accession_number":"NCT03520686","excerpt":"There are no longer active subjects on QUILT-2.023. Data will be entered into clinicaltrials.gov within 1 year of the primary completion date.","importance":80},{"ts":"2026-04-15","kind":"clinical.trial","reporter":"ImmunityBio, Inc.","title":"HCW9218 for Advanced Pancreatic Cancer","security_title":"PHASE1,PHASE2","status":"COMPLETED","accession_number":"NCT05304936","excerpt":"[\"Advanced Pancreatic Carcinoma\"]","importance":45},{"ts":"2026-04-01","kind":"clinical.trial","reporter":"ImmunityBio, Inc.","title":"Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT05618925","excerpt":"[\"Non Hodgkin's Lymphoma Refractory/Relapsed\"]","importance":30},{"ts":"2026-04-01","kind":"clinical.trial","reporter":"ImmunityBio, Inc.","title":"QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT04050709","excerpt":"[\"Locally Advanced Solid Tumor\",\"Metastatic Cancer\",\"Solid Tumor\"]","importance":30},{"ts":"2026-03-31","kind":"clinical.trial","reporter":"ImmunityBio, Inc.","title":"A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer","security_title":"PHASE1,PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT02138734","excerpt":"[\"Non-muscle Invasive Bladder Cancer\"]","importance":45},{"ts":"2026-03-27","kind":"clinical.trial","reporter":"ImmunityBio, Inc.","title":"ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06800963","excerpt":"[\"NMIBC\"]","importance":45},{"ts":"2026-03-26","kind":"court.docket","reporter":"cacd","title":"Jeremiah Douglas v. ImmunityBio, Inc.","security_title":"850 Securities/Commodities","excerpt":"15:78m(a) Securities Exchange Act","accession_number":"2:26-cv-03261","product_type":"Otis D. Wright II","importance":45},{"ts":"2024-12-31","kind":"open.payments","reporter":"IMMUNITYBIO, INC.","title":"$67804.0 to 1282 physicians (2024–2024)","security_title":"manufacturer","excerpt":"ANKTIVA","accession_number":"2024","usd_value":67804,"importance":70}]}